DE69702527D1 - Krebs therapie - Google Patents

Krebs therapie

Info

Publication number
DE69702527D1
DE69702527D1 DE69702527T DE69702527T DE69702527D1 DE 69702527 D1 DE69702527 D1 DE 69702527D1 DE 69702527 T DE69702527 T DE 69702527T DE 69702527 T DE69702527 T DE 69702527T DE 69702527 D1 DE69702527 D1 DE 69702527D1
Authority
DE
Germany
Prior art keywords
compound
vascular compartment
cancer therapy
mammal
following administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69702527T
Other languages
English (en)
Other versions
DE69702527T2 (de
Inventor
Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzacta R&D Ltd
Original Assignee
Enzacta R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R&D Ltd filed Critical Enzacta R&D Ltd
Application granted granted Critical
Publication of DE69702527D1 publication Critical patent/DE69702527D1/de
Publication of DE69702527T2 publication Critical patent/DE69702527T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69702527T 1996-11-30 1997-11-28 Krebs therapie Expired - Fee Related DE69702527T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624993.3A GB9624993D0 (en) 1996-11-30 1996-11-30 Tumour therapy
PCT/GB1997/003284 WO1998024478A2 (en) 1996-11-30 1997-11-28 Tumour therapy

Publications (2)

Publication Number Publication Date
DE69702527D1 true DE69702527D1 (de) 2000-08-17
DE69702527T2 DE69702527T2 (de) 2001-03-08

Family

ID=10803777

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69702527T Expired - Fee Related DE69702527T2 (de) 1996-11-30 1997-11-28 Krebs therapie

Country Status (11)

Country Link
EP (1) EP0918545B1 (de)
JP (1) JP2001505220A (de)
AT (1) ATE194499T1 (de)
CA (1) CA2273218A1 (de)
DE (1) DE69702527T2 (de)
DK (1) DK0918545T3 (de)
ES (1) ES2150286T3 (de)
GB (1) GB9624993D0 (de)
GR (1) GR3034592T3 (de)
PT (1) PT918545E (de)
WO (1) WO1998024478A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9812550D0 (en) * 1998-06-11 1998-08-05 Aepact Ltd Tumour therapy and imaging
JP2005517674A (ja) * 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
PL3377103T3 (pl) 2015-11-19 2021-10-04 Revitope Limited Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
JP2000502698A (ja) * 1995-12-29 2000-03-07 エンザクタ アール アンド ディ リミテッド 細胞毒性試薬

Also Published As

Publication number Publication date
ES2150286T3 (es) 2000-11-16
EP0918545B1 (de) 2000-07-12
WO1998024478A3 (en) 1998-07-30
EP0918545A2 (de) 1999-06-02
JP2001505220A (ja) 2001-04-17
WO1998024478A2 (en) 1998-06-11
CA2273218A1 (en) 1998-06-11
ATE194499T1 (de) 2000-07-15
DE69702527T2 (de) 2001-03-08
PT918545E (pt) 2000-12-29
GB9624993D0 (en) 1997-01-15
GR3034592T3 (en) 2001-01-31
DK0918545T3 (da) 2000-11-27

Similar Documents

Publication Publication Date Title
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
NO996120D0 (no) Imidazolyl-cykliske acetaler
MY122383A (en) Cyclic boroproline compounds
DE69702527T2 (de) Krebs therapie
GB2083818B (en) Amidine compounds
CA2145093A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
NO890103D0 (no) Fremgangsmaate for fremstilling av levende vaksine mot coccidiosis.
EP0972517A3 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
TR200001253T2 (tr) Tümöre özel antijenler
IS2216B (is) Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
TR199903074T2 (xx) Kanser tedavisinde HMG CoA ve farnesil transfer �nleyicileri.
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
MX9204528A (es) 0etodo para tratar el sindrome premenstrual mediante administracion de un inhibidor de la enzima de conversion de angiotensina.
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
NO904003L (no) 1,2,4-benzotriazinoksider som radiosensibiliseringsmidlerog selektive cytotoksiske midler.
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
EP0664281A4 (de)
Irby Echoes.(Original writing);.
RU99122488A (ru) Способ лечения рака эндометрия

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee